Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease.

Bakker WM, Heerspink HJL, Berger SP, Wanner C, Badve SV, Arnott C, Abrahams AC, van den Born JC, van Faassen TC, Gaillard CAJM, Gelens MACJ, Górris JL, Hemmelder MH, Jakulj L, van Kruijsdijk RCM, Kuypers DRJ, van der Meer P, van der Net JB, Nijmeijer HH, Vervloet MG, de Vries APJ, Walsh M, Wang AY, Gansevoort RT, Renal Lifecycle Trial Investigators

Open source

DOI: 10.1093/ndt/gfaf046
Published: 2025 Aug 29
Container: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/ndt/gfaf046,
  title = {Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease.},
  author = {Bakker WM and Heerspink HJL and Berger SP and Wanner C and Badve SV and Arnott C and Abrahams AC and van den Born JC and van Faassen TC and Gaillard CAJM and Gelens MACJ and Górris JL and Hemmelder MH and Jakulj L and van Kruijsdijk RCM and Kuypers DRJ and van der Meer P and van der Net JB and Nijmeijer HH and Vervloet MG and de Vries APJ and Walsh M and Wang AY and Gansevoort RT and Renal Lifecycle Trial Investigators},
  year = {2025},
  journal = {Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association},
  doi = {10.1093/ndt/gfaf046},
  url = {https://doi.org/10.1093/ndt/gfaf046}
}

RIS

TY  - JOUR
TI  - Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease.
AU  - Bakker WM
AU  - Heerspink HJL
AU  - Berger SP
AU  - Wanner C
AU  - Badve SV
AU  - Arnott C
AU  - Abrahams AC
AU  - van den Born JC
AU  - van Faassen TC
AU  - Gaillard CAJM
AU  - Gelens MACJ
AU  - Górris JL
AU  - Hemmelder MH
AU  - Jakulj L
AU  - van Kruijsdijk RCM
AU  - Kuypers DRJ
AU  - van der Meer P
AU  - van der Net JB
AU  - Nijmeijer HH
AU  - Vervloet MG
AU  - de Vries APJ
AU  - Walsh M
AU  - Wang AY
AU  - Gansevoort RT
AU  - Renal Lifecycle Trial Investigators
PY  - 2025
JO  - Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
DO  - 10.1093/ndt/gfaf046
UR  - https://doi.org/10.1093/ndt/gfaf046
ER  -

APA

WM, B., HJL, H., SP, B., C, W., SV, B., C, A., AC, A., JC, V. D. B., TC, V. F., CAJM, G., MACJ, G., JL, G., MH, H., L, J., RCM, V. K., DRJ, K., P, V. D. M., JB, V. D. N., HH, N., MG, V., APJ, D. V., M, W., AY, W., RT, G., & Investigators, R. L. T. (2025). Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease.. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. https://doi.org/10.1093/ndt/gfaf046

Source records

pubmed · retrieved 2026-09-26T04:40:40.654Z
europe-pmc · retrieved 2026-09-26T04:40:40.656Z